Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid Tumors

NCT03525925 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT03525925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03525925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid Tumors
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
July 18, 2018
Completion date
July 31, 2022
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant solid neoplasm